SRAX Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 0/6

Unzureichende Daten zur Bestimmung der Gesundheit von SRAX

Wichtige Informationen

n/a

Verhältnis von Schulden zu Eigenkapital

n/a

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	n/a
Eigenkapital	n/a
Gesamtverbindlichkeiten	n/a
Gesamtvermögen	n/a

Jüngste Berichte zur Finanzlage

Is SRAX (NASDAQ:SRAX) A Risky Investment?

Dec 06

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: Unzureichende Daten, um festzustellen, ob die kurzfristigen Vermögenswerte von SRAX die kurzfristigen Verbindlichkeiten decken.

Langfristige Verbindlichkeiten: Unzureichende Daten, um festzustellen, ob die kurzfristigen Vermögenswerte von SRAX die langfristigen Verbindlichkeiten decken.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: Es liegen keine ausreichenden Daten vor, um den Nettoverschuldungsgrad von SRAX zu berechnen und festzustellen, ob er zufriedenstellend ist.

Schulden abbauen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob das Verhältnis von Schulden zu Eigenkapital in den letzten 5 Jahren gesunken ist ( SRAX).

Schuldendeckung: Unzureichende Daten, um festzustellen, ob die Schulden von SRAXgut durch den operativer Cashflow gedeckt sind.

Zinsdeckung: Unzureichende Daten, um zu bestimmen, ob die Zinszahlungen von SRAX für seine Schulden durch das EBIT gut gedeckt sind.

SRAX Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

SRAX Announces Receipt of Nasdaq Listing Determination

SRAX Announces Receipt of Anticipated Nasdaq Notice of Additional Delinquency

SRAX, Inc. announced delayed 10-Q filing

SRAX, Inc. Receives Non-Compliance Notice from Nasdaq

SRAX, Inc. announced delayed annual 10-K filing

Is SRAX (NASDAQ:SRAX) A Risky Investment?

Recent updates

DNA Holdings LLC entered into a definitive merger agreement to acquire remaining 65% stake in SRAX, Inc. (OTCPK:SRAX).

SRAX, Inc. announced that it has received $0.075 million in funding

SRAX, Inc. announced that it has received $0.075 million in funding

SRAX, Inc. Announces Resignation of Board Members

Alan Urban Resigns as the Chief Financial Officer of SRAX, Inc

New major risk - Market cap size

First quarter 2022 earnings released: EPS: US$0.14 (vs US$0.57 loss in 1Q 2021)

Forecast breakeven date pushed back to 2023

SRAX, Inc., Annual General Meeting, Dec 31, 2022

Price target increased to US$10.50

SRAX, Inc. Launches the Sequire Investor Community Platform

SRAX Announces Receipt of Nasdaq Listing Determination

SRAX gets Nasdaq delisting notice, plans to appeal decision

Full year 2021 earnings released: US$0.41 loss per share (vs US$0.69 loss in FY 2020)

SRAX, Inc. Announces the Arcimoto Sweepstakes

SRAX Announces Receipt of Anticipated Nasdaq Notice of Additional Delinquency

Srax receives Nasdaq notice of additional delinquency

Is There An Opportunity With SRAX, Inc.'s (NASDAQ:SRAX) 50% Undervaluation?

Price target increased to US$10.50

SRAX announces $9.5M revolving credit facility

SRAX, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

SRAX, Inc. announced delayed 10-Q filing

SRAX, Inc. Receives Non-Compliance Notice from Nasdaq

SRAX, Inc. announced delayed annual 10-K filing

SRAX, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Is SRAX (NASDAQ:SRAX) A Risky Investment?

SRAX Offers Value Here

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.38 loss in 2Q 2020)

Does SRAX (NASDAQ:SRAX) Have A Healthy Balance Sheet?

SRAX Is Booming, Except The Share Price

Consensus forecasts updated

SRAX, Inc. (NasdaqCM:SRAX) announces an Equity Buyback for $10 million worth of its shares.

Price target increased to US$9.75

SRAX Releases the 1x1 Meeting Feature on the Sequire Virtual Events Platform

SRAX Has Plenty Of Room To Run

SRAX, Inc. announced delayed 10-Q filing

SRAX, Inc. Provides Revenue Guidance for the Second Quarter of Fiscal 2021

Full year 2020 earnings released: US$0.92 loss per share (vs US$1.36 loss in FY 2019)

SRAX, Inc. Provides Revenue Guidance for the Second Quarter Of Fiscal Year 2021

SRAX, Inc. Releases the Shelf Registration Feature on the Sequire Platform

Brock Pierce Joins SRAX Board of Directors

SRAX trades high on Sequire platform reporting 3M retail investors

New 90-day high: US$3.95

Does SRAX (NASDAQ:SRAX) Have A Healthy Balance Sheet?

New 90-day high: US$3.12

Analysts update estimates

SRAX, Inc., Annual General Meeting, Dec 31, 2020

Third quarter 2020 earnings released: US$0.45 loss per share

SRAX EPS misses by $0.14, beats on revenue

An undisclosed buyer acquired the remaining stake in the MD Asset of SRAX, Inc. (NasdaqCM:SRAX) for $8 million.

New 90-day low: US$2.34

SRAX, Inc. Announces Resignation of Kristoffer Nelson as Chief Operating Officer and as a Member of the Board, Effective October 16, 2020

SRAX, Inc. announced that it has received $14 million in funding from Serra Ventures, LLC

SRAX, Inc. (NasdaqCM:SRAX) completed the acquisition of LD Micro, Inc.

Analysts increase revenue estimates to US$5.72m

Analysts update estimates

New 90-day high - US$2.80

SRAX, Inc. announced that it has received $13 million in funding

SRAX, Inc.(NasdaqCM:SRAX) dropped from Russell Microcap Growth Index

SRAX, Inc. announced that it has received $11.8 million in funding

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen